Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82. - Najera SS; Ricketts CJ; Schmidt LS; Medina JI; Saito K; Ileva L; Brender JR; James AM; Peer CJ; Gouker B; Karim BO; Chernova O; et al. (Molecular cancer therapeutics, 2025)